Prognostic factors in chronic hypersensitivity pneumonitis

by Andrew W. Creamer, Shaney L. Barratt
Published 2020-05-01

Does ambulatory oxygen improve quality of life in patients with fibrotic lung disease? Results from the AmbOx trial

by Andrew W. Creamer, Shaney L. Barratt
Published 2019-06-01

Idiopathic Pulmonary Fibrosis (IPF): An Overview

by Shaney L. Barratt, Andrew Creamer, Conal Hayton, Nazia Chaudhuri
Published 2018-08-01

The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review

by Shaney L. Barratt, Richard Davis, Charles Sharp, John D. Pauling
Published 2020-08-01

VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease

by Shaney L. Barratt, Victoria A. Flower, John D. Pauling, Ann B. Millar
Published 2018-04-01

VEGF isoforms have differential effects on permeability of human pulmonary microvascular endothelial cells

by Khadija Ourradi, Thomas Blythe, Caroline Jarrett, Shaney L. Barratt, Gavin I. Welsh, Ann B. Millar
Published 2017-06-01

Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)

by Shaney L. Barratt, Thomas Blythe, Khadija Ourradi, Caroline Jarrett, Gavin I. Welsh, David O. Bates, Ann B. Millar
Published 2018-01-01

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

by Shaney L. Barratt, Sarah Mulholland, Khaled Al Jbour, Henry Steer, Markus Gutsche, Noeleen Foley, Rajiv Srivastava, Charles Sharp, Huzaifa I. Adamali
Published 2018-12-01